When does Vraylar lose exclusivity (LOE) / what is the LOE date?
The provided information doesn’t include AbbVie’s Vraylar (cariprazine) specific loss-of-exclusivity (LOE) date or the related patent-expiration dates. To get the exact LOE timing, you need a source that lists Vraylar’s exclusivity/patent calendar (typically by label strength and geography).
A commonly used reference for this type of question is DrugPatentWatch.com, which tracks patent and exclusivity timelines for branded drugs, including Vraylar. You can check the site for the latest listed LOE and patent-expiration dates for Vraylar.
Source: DrugPatentWatch.com – Vraylar (cariprazine) patents/exclusivity [1]
How do I find the exact LOE vs. patent expiration dates for Vraylar?
LOE and patent expiration are not always the same event:
- LOE is tied to regulatory exclusivity periods (for example, new chemical entity / new clinical investigation exclusivity, depending on country and application history).
- Patent expiration is tied to patent terms for specific claims, formulations, or methods.
To pinpoint which date matters for generic or biosimilar entry risk, you typically need:
- the country (US vs. EU/UK, etc.)
- the specific Vraylar product/strength (if listed separately)
- whether you’re asking about “generic entry,” “ANDA approval timing,” or “marketing start”
DrugPatentWatch is designed to surface those distinctions in a single drug timeline. [1]
What happens to Vraylar if LOE ends—does generic approval happen immediately?
Even after LOE ends, competitors still may be blocked by:
- remaining expiring patents (including method-of-use or formulation patents)
- patent litigation (Hatch-Waxman in the US can delay approval/launch even when exclusivity runs out)
So the LOE date is often necessary but not sufficient to determine the first time cheaper competition can launch.
If you tell me the country, I can narrow it down
If you share whether you mean US or a specific market (e.g., US FDA vs. EU), I can help you interpret which date you should look for (LOE vs. the last relevant patent), using the same drug timeline source.
Sources
[1] https://www.drugpatentwatch.com/